Presentation Stock market days at Aktiespararna
June, 2025
Presenter:
Martin Åmark, CEO
Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.
We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.
We develop biosimilars in treatment of macular degeneration (Xlucane™) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion
June, 2025
Presenter:
Martin Åmark, CEO
11 Jun 2026
Xbrane Biopharma AB and JOINN Biologics US Inc. Enter Strategic Partnership to Develop Xdarzane – Xbrane´s Biosimilar Candidate to Darzalex® (Daratumumab)
03 Jun 2026
Xbrane Biopharma AB (publ) (“Xbrane” or “the Company”) (Nasdaq Stockholm: XBRANE) receives FDA BsUFA date of October 29, 2026 for its investigational biosimilar candidate to LUCENTIS® (ranibizumab)
05 May 2026
Xbrane Biopharma AB’s (publ.) (”Xbrane”) Interim Report January-March 2026, is as of today, available on the Company’s website, www.xbrane.com.
05 May 2026
Xbrane and its partner Intas agree on revised financing arrangement for Xbrane’s Xdivane development activities